Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease

Andrea Martinuzzi, Alexandra Liava, Enrico Trevisi, Mara Frare, Caterina Tonon, Emil Malucelli, David Manners, Graham J. Kemp, Claudia Testa, Bruno Barbiroli, Raffaele Lodi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

McArdle's disease causes limitation in exercise capacity as well as disability, the severity of which has been associated with the angiotensin-converting enzyme (ACE) insertion (I)/deletion (D) haplotype - patients with the genotype associated with higher ACE activity show the most severe phenotype. Modulation of ACE activity through the use of inhibitors may thus positively affect disease expression. In a double-blind, randomized, placebo-controlled trial, we assessed the efficacy of an ACE inhibitor (2.5 mg ramipril) in 8 patients with McArdle's disease. End-points were changes in parameters of exercise physiology (cycloergometer and muscle 31P-magnetic resonance spectroscopy), quality of life (QoL) according to the Short Form 36 (SF-36), and disability according to the World Health Organization-Disability Assessment Scale II (WHO-DAS II). Patients had lower QoL and higher disability than controls. Measures of exercise physiology were not changed by ramipril in the whole group, but treatment induced higher peak VO2 (P = 0.017) in ACE D/D patients, yet not in I/D patients. Treatment significantly improved disability (P <0.05). McArdle's disease is a disabling condition affecting patients' QoL. Treatment with ramipril improves disability and modifies exercise physiology only in D/D patients, raising the possibility of a differential haplotype-linked sensitivity to the treatment.

Original languageEnglish
Pages (from-to)350-357
Number of pages8
JournalMuscle and Nerve
Volume37
Issue number3
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Glycogen Storage Disease Type V
Ramipril
Placebos
Peptidyl-Dipeptidase A
Exercise
Quality of Life
Haplotypes
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Magnetic Resonance Spectroscopy
Randomized Controlled Trials
Genotype
Phenotype
Muscles

Keywords

  • ACE inhibitor
  • McArdle's disease
  • Muscle glycogenosis
  • Ramipril
  • Therapeutic trial

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Martinuzzi, A., Liava, A., Trevisi, E., Frare, M., Tonon, C., Malucelli, E., ... Lodi, R. (2008). Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. Muscle and Nerve, 37(3), 350-357. https://doi.org/10.1002/mus.20937

Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. / Martinuzzi, Andrea; Liava, Alexandra; Trevisi, Enrico; Frare, Mara; Tonon, Caterina; Malucelli, Emil; Manners, David; Kemp, Graham J.; Testa, Claudia; Barbiroli, Bruno; Lodi, Raffaele.

In: Muscle and Nerve, Vol. 37, No. 3, 03.2008, p. 350-357.

Research output: Contribution to journalArticle

Martinuzzi, A, Liava, A, Trevisi, E, Frare, M, Tonon, C, Malucelli, E, Manners, D, Kemp, GJ, Testa, C, Barbiroli, B & Lodi, R 2008, 'Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease', Muscle and Nerve, vol. 37, no. 3, pp. 350-357. https://doi.org/10.1002/mus.20937
Martinuzzi, Andrea ; Liava, Alexandra ; Trevisi, Enrico ; Frare, Mara ; Tonon, Caterina ; Malucelli, Emil ; Manners, David ; Kemp, Graham J. ; Testa, Claudia ; Barbiroli, Bruno ; Lodi, Raffaele. / Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. In: Muscle and Nerve. 2008 ; Vol. 37, No. 3. pp. 350-357.
@article{51a9c6595ee84f9eb6bf5112ded3f66d,
title = "Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease",
abstract = "McArdle's disease causes limitation in exercise capacity as well as disability, the severity of which has been associated with the angiotensin-converting enzyme (ACE) insertion (I)/deletion (D) haplotype - patients with the genotype associated with higher ACE activity show the most severe phenotype. Modulation of ACE activity through the use of inhibitors may thus positively affect disease expression. In a double-blind, randomized, placebo-controlled trial, we assessed the efficacy of an ACE inhibitor (2.5 mg ramipril) in 8 patients with McArdle's disease. End-points were changes in parameters of exercise physiology (cycloergometer and muscle 31P-magnetic resonance spectroscopy), quality of life (QoL) according to the Short Form 36 (SF-36), and disability according to the World Health Organization-Disability Assessment Scale II (WHO-DAS II). Patients had lower QoL and higher disability than controls. Measures of exercise physiology were not changed by ramipril in the whole group, but treatment induced higher peak VO2 (P = 0.017) in ACE D/D patients, yet not in I/D patients. Treatment significantly improved disability (P <0.05). McArdle's disease is a disabling condition affecting patients' QoL. Treatment with ramipril improves disability and modifies exercise physiology only in D/D patients, raising the possibility of a differential haplotype-linked sensitivity to the treatment.",
keywords = "ACE inhibitor, McArdle's disease, Muscle glycogenosis, Ramipril, Therapeutic trial",
author = "Andrea Martinuzzi and Alexandra Liava and Enrico Trevisi and Mara Frare and Caterina Tonon and Emil Malucelli and David Manners and Kemp, {Graham J.} and Claudia Testa and Bruno Barbiroli and Raffaele Lodi",
year = "2008",
month = "3",
doi = "10.1002/mus.20937",
language = "English",
volume = "37",
pages = "350--357",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease

AU - Martinuzzi, Andrea

AU - Liava, Alexandra

AU - Trevisi, Enrico

AU - Frare, Mara

AU - Tonon, Caterina

AU - Malucelli, Emil

AU - Manners, David

AU - Kemp, Graham J.

AU - Testa, Claudia

AU - Barbiroli, Bruno

AU - Lodi, Raffaele

PY - 2008/3

Y1 - 2008/3

N2 - McArdle's disease causes limitation in exercise capacity as well as disability, the severity of which has been associated with the angiotensin-converting enzyme (ACE) insertion (I)/deletion (D) haplotype - patients with the genotype associated with higher ACE activity show the most severe phenotype. Modulation of ACE activity through the use of inhibitors may thus positively affect disease expression. In a double-blind, randomized, placebo-controlled trial, we assessed the efficacy of an ACE inhibitor (2.5 mg ramipril) in 8 patients with McArdle's disease. End-points were changes in parameters of exercise physiology (cycloergometer and muscle 31P-magnetic resonance spectroscopy), quality of life (QoL) according to the Short Form 36 (SF-36), and disability according to the World Health Organization-Disability Assessment Scale II (WHO-DAS II). Patients had lower QoL and higher disability than controls. Measures of exercise physiology were not changed by ramipril in the whole group, but treatment induced higher peak VO2 (P = 0.017) in ACE D/D patients, yet not in I/D patients. Treatment significantly improved disability (P <0.05). McArdle's disease is a disabling condition affecting patients' QoL. Treatment with ramipril improves disability and modifies exercise physiology only in D/D patients, raising the possibility of a differential haplotype-linked sensitivity to the treatment.

AB - McArdle's disease causes limitation in exercise capacity as well as disability, the severity of which has been associated with the angiotensin-converting enzyme (ACE) insertion (I)/deletion (D) haplotype - patients with the genotype associated with higher ACE activity show the most severe phenotype. Modulation of ACE activity through the use of inhibitors may thus positively affect disease expression. In a double-blind, randomized, placebo-controlled trial, we assessed the efficacy of an ACE inhibitor (2.5 mg ramipril) in 8 patients with McArdle's disease. End-points were changes in parameters of exercise physiology (cycloergometer and muscle 31P-magnetic resonance spectroscopy), quality of life (QoL) according to the Short Form 36 (SF-36), and disability according to the World Health Organization-Disability Assessment Scale II (WHO-DAS II). Patients had lower QoL and higher disability than controls. Measures of exercise physiology were not changed by ramipril in the whole group, but treatment induced higher peak VO2 (P = 0.017) in ACE D/D patients, yet not in I/D patients. Treatment significantly improved disability (P <0.05). McArdle's disease is a disabling condition affecting patients' QoL. Treatment with ramipril improves disability and modifies exercise physiology only in D/D patients, raising the possibility of a differential haplotype-linked sensitivity to the treatment.

KW - ACE inhibitor

KW - McArdle's disease

KW - Muscle glycogenosis

KW - Ramipril

KW - Therapeutic trial

UR - http://www.scopus.com/inward/record.url?scp=39749147331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749147331&partnerID=8YFLogxK

U2 - 10.1002/mus.20937

DO - 10.1002/mus.20937

M3 - Article

C2 - 18098237

AN - SCOPUS:39749147331

VL - 37

SP - 350

EP - 357

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 3

ER -